Volume 5, Issue 4 pp. 282-285

c-erbB-3 proto-oncogene expression in uterine cervical carcinoma

C.R. Hunt

C.R. Hunt

Department of Pathology, St Mary’s Hospital, Manchester,

Search for more papers by this author
R.J. Hale

R.J. Hale

Stepping Hill Hospital, Stockport,

Search for more papers by this author
C. Armstrong

C. Armstrong

Bury General Hospital,

Search for more papers by this author
T. Rajkumar

T. Rajkumar

ICRF Oncology Unit, Hammersmith Hospital, London, UK

Search for more papers by this author
W.J. Gullick

W.J. Gullick

ICRF Oncology Unit, Hammersmith Hospital, London, UK

Search for more papers by this author
C.H. Buckley

C.H. Buckley

Department of Pathology, St Mary’s Hospital, Manchester,

Search for more papers by this author
First published: July/August 1995
Citations: 2
Address for correspondence: Dr R. J. Hale, Department of Histopathology, Stockport Acute Services NHS Trust, Stepping Hill Hospital, Stockport, Cheshire SK2 7JE, UK.

Abstract

Over-expression of epidermal growth factor receptor (EGFR) and c-erbB-2, in uterine cervical carcinomas, is associated with a worsened prognosis. A third member of this proto-oncogene family, c-erbB-3, has now been identified and its over-expression has been described in a variety of carcinomas. In this immunohistochemical study we have shown that c-erbB-3 is widely expressed in cervical carcinomas, but we have found no association between its over-expression and lymph node status or clinical outcome. In a similar study examining the expression of EGFR and c-erbB-2 it was possible to demonstrate an association between over-expression and a worse prognosis. We conclude, therefore, that it is unlikely that demonstration of c-erbB-3 over-expression will be of any value as a prognostic indicator in carcinoma of the uterine cervix.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.